Clinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer
Recruiting · NCT07477158 · Observational (researchers observe without assigning treatment) · Lead sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
View the official record on ClinicalTrials.gov →What this trial is about
The goal is to compare patient reported outcomes, such as dyspnea, physical functioning and quality of life, between minimally invasive segmentectomy and lobectomy for stage I NSCLC during the first year after surgery. The main questions it aims to answer are: * Do patients with stage I NSCLC that undergo minimally invasive segmentectomy have less postoperative dyspnea than patients that undergo lobectomy? * Do patients with stage I NSCLC that undergo minimally invasive segmentectomy have more favorable postoperative health related quality of life (HRQoL) than patients that undergo lobectomy? * Do patients with stage I NSCLC that undergo VATS segmentectomy or lobectomy have more favorable postoperative health related quality of life (HRQoL) than patients that undergo RATS segmentectomy or lobectomy? Participants already undergoing surgical intervention as part of their regular medical care for resectable lung cancer will answer quality of life questionnaires preoperatively, at 1, 3, 6, and 12 months after surgery.
Who can take part
Inclusion criteria
- Patients with clinical stage I NSCLC who undergo segmentectomy or lobectomy with VATS or RATS.
Exclusion criteria
- Thoracic surgery in the previous year
- Neoadyuvant treatment
- Failure to complete preoperative questionnaires
Where it is running
1 location listed.
- Hospital Universitario Ramón y Cajal - Madrid, Madrid, Spain